DeepMed Research

Glucagon

Generic Name: Glucagon

Brand Names: Baqsimi, Glucagen, Gvoke, Ogluo

Drug Type: Biotech

CAS Number: 16941-32-5

Unique Ingredient Identifier: 76LA80IG2G

Background: Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.

Glucagon was granted FDA approval on 14 November 1960.

Indication: Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.

Associated Conditions: Severe Hypoglycemia

Clinical Trials

Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes

Phase 2

Completed

Conditions: Type 1 Diabetes

Interventions: Other: 15-hour intervention
Drug: Insulin (Lispro, Aspart or guilisine)
Drug: Glucagon (Eli Lilly)
Other: Closed-loop strategy

First Posted Date: 2015-04-15

Last Posted Date: 2015-11-16

Lead Sponsor: Institut de Recherches Cliniques de Montreal

Target Recruit Count: 15

Registration Number: NCT02416765

Locations: 🇨🇦
Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada

Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons

Phase 1

Completed

Conditions: Hypoglycemia

Interventions: Drug: BIOD-961
Drug: Lilly Glucagon
Drug: Novo Glucagon

First Posted Date: 2015-03-31

Last Posted Date: 2016-01-15

Lead Sponsor: Biodel

Target Recruit Count: 15

Registration Number: NCT02403648

Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

Phase 3

Completed

Conditions: Hypoglycemia
Diabetes Mellitus

Interventions: Drug: Nasal Glucagon

First Posted Date: 2015-03-30

Last Posted Date: 2019-09-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT02402933

Locations: 🇺🇸
Private Clinic, Baltimore, Maryland, United States
🇺🇸
New England Diabetes and Endocrinology Center (NEDEC), Waltham, Massachusetts, United States

Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator

Phase 1

Completed

Conditions: Hypoglycemia

Interventions: Drug: ZP4207
Drug: Glucagon

First Posted Date: 2015-02-20

Last Posted Date: 2016-01-22

Lead Sponsor: Zealand Pharma

Target Recruit Count: 111

Registration Number: NCT02367053

Locations: 🇩🇪
Profil GmbH, Neuss, Germany

Effects of Glucagon Administration on Energy Expenditure

Phase 1

Completed

Conditions: Hyperglucagonemia
Obesity

Interventions: Drug: Glucagon
Drug: Octreotide
Behavioral: Placebo
Drug: Insulin

First Posted Date: 2014-09-11

Last Posted Date: 2018-04-26

Lead Sponsor: AdventHealth Translational Research Institute

Target Recruit Count: 6

Registration Number: NCT02237053

Locations: 🇺🇸
Florida Hospital Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States

Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes

Phase 4

Conditions: Diabetes Mellitus, Type 1

Interventions: Other: Isotonic saline solution
Drug: Glucagon

First Posted Date: 2014-09-05

Last Posted Date: 2015-03-25

Lead Sponsor: Hvidovre University Hospital

Target Recruit Count: 8

Registration Number: NCT02232971

Locations: 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark

Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia

Phase 3

Completed

Conditions: Diabetes Mellitus
Drug-Specific Antibodies
Hypoglycemia

Interventions: Drug: Nasal Glucagon

First Posted Date: 2014-06-24

Last Posted Date: 2019-10-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 129

Registration Number: NCT02171130

Locations: 🇨🇦
Centre de recherche d'endocrinologie Godin & St-Pierre, Sherbrooke, Quebec, Canada
🇺🇸
New England Diabetes and Endocrinology Center (NEDEC), Waltham, Massachusetts, United States
🇨🇦
Winnipeg Clinic, Winnipeg, Manitoba, Canada

and more 6 locations

Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)

Phase 1

Completed

Conditions: Hypoglycemia

Interventions: Drug: Glucagon for Injection (Fresenius Kabi USA)
Drug: Glucagon for Injection (Bedford Laboratories)

First Posted Date: 2014-03-13

Last Posted Date: 2014-03-13

Lead Sponsor: Fresenius Kabi USA, LLC

Target Recruit Count: 32

Registration Number: NCT02086227

Locations: 🇺🇸
West Houston Clinical Research Services, 2026 Wirt Road, Houston, Texas, United States

Glucagon Use in Colonoscopies

Phase 4

Completed

Conditions: Colon Cancer

Interventions: Drug: Glucagon

First Posted Date: 2014-03-05

Last Posted Date: 2021-04-20

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 100

Registration Number: NCT02078726

Locations: 🇺🇸
San Francisco General Hospital, San Francisco, California, United States

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

Phase 2

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Xeris glucagon
Drug: Lilly glucagon

First Posted Date: 2013-12-23

Last Posted Date: 2019-10-08

Lead Sponsor: Steven J. Russell, MD, PhD

Target Recruit Count: 20

Registration Number: NCT02018627

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy